Triana Biomedicines
Last verified 2026-04-29. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $230.0Mattributed |
|---|---|
| Latest round | series-b, $120.0M, 2025-12-01attributed |
| Founded | 2019 |
| Headquarters | Lexington, United States |
| Industry | bio |
| Stage | series-b+ |
| Website | trianabio.com |
Triana Biomedicines develops molecular glue degraders, small molecules that force a disease-causing protein together with the cell's degradation machinery. It targets cancer patients whose disease is driven by proteins long considered undruggable. Its protein-pairing engine identifies matching E3 ligases, engineering glues rationally not by chance.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-12-01 | series-b | $120.0M | undisclosed |
Detected tech stack
Typekit, Adobe Fonts, Afterpay, Sentry, Squarespace, Squarespace Commerce, Stimulus, web-vitals, moment 0, @sentry/browser
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $120.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $230.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | trianabio.com, read 2026-04-29 |
| Description | self-reported | trianabio.com, read 2026-04-29 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.